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The novel protein KIAA1199 is overproduced by Crohn’s
disease mesenchymal cells in vivo and in vitro. KIAA1199 is
important for generating proinﬂammatory and proﬁbrotic
hyaluronan fragments. Interleukin 6, overproduced by
Crohn’s disease cells, regulates deposition of KIAA1199 by
ﬁbroblasts.
BACKGROUND & AIMS: Crohn’s Disease (CD) is a chronic
inﬂammatory disease of the gastrointestinal tract. Fibrosis, a
serious complication of CD, occurs when activated intestinal
ﬁbroblasts deposit excessive amounts of extracellular matrix
(ECM) in affected areas. A major component of the ECM is
high-molecular-weight hyaluronan (HA) that, when depoly-
merized to low-molecular-weight fragments, becomes
proinﬂammatory and proﬁbrotic. Mechanisms for HA degra-
dation are incompletely understood, but the novel protein
KIAA1199 recently was discovered to degrade HA. We
hypothesized that KIAA1199 protein is increased in CD colon
ﬁbroblasts and generates HA fragments that foster inﬂam-
mation and ﬁbrosis.
METHODS: Fibroblasts were isolated from explants of surgi-
cally resected colon tissue from CD and non–inﬂammatory
bowel disease control (ND) patients. Protein levels and tissue
distribution of KIAA1199 were assessed by immunoblot and
immunostaining, and functional HA degradation was measured
biochemically.
RESULTS: Increased levels of KIAA1199 protein were pro-
duced and deposited in the ECM by cultured CD ﬁbroblasts
compared with controls. Treatment of ﬁbroblasts with the
proinﬂammatory cytokine interleukin (IL) 6 increased deposi-
tion of KIAA1199 in the ECM. CD ﬁbroblasts also produce
signiﬁcantly higher levels of IL6 compared with controls, and
antibody blockade of IL6 receptors in CD colon ﬁbroblasts
decreased the level of KIAA1199 protein in the ECM. Colon
ﬁbroblasts degrade HA, however, small interfering RNA
silencing of KIAA1199 abrogated that ability.
CONCLUSIONS: CD ﬁbroblasts produce increased levels of
KIAA1199 primarily through an IL6-driven autocrine mecha-
nism. This leads to excessive degradation of HA and the gen-
eration of proinﬂammatory HA fragments, which contributes to
maintenance of gut inﬂammation and ﬁbrosis. (Cell Mol Gas-
troenterol Hepatol 2016;2:358–368; http://dx.doi.org/10.1016/
j.jcmgh.2015.12.007)Keywords: Crohn’s Disease; Fibrosis; Hyaluronan; KIAA1199.
rohn’s disease (CD) is a chronic inﬂammatory con-Cdition that may affect the whole gastrointestinal
tract and lead to serious complications, among which are
ﬁbrosis and stricture formation.1,2 During the development
of intestinal ﬁbrosis, activated ﬁbroblasts and myoﬁbro-
blasts proliferate and deposit extracellular matrix (ECM)
components in the affected areas.3,4 Prolonged ﬁbrosis
ultimately leads to stiffening and thickening of the bowel
wall, eventually occluding the lumen and causing intestinal
obstruction, frequently necessitating surgical intervention
for relief.5
The intestinal ECM, similar to that of other tissues, is
composed of a complex network of proteins and pro-
teoglycans that surround all cells and function with both
structural and signaling capacities.6 A particular ECM
component of interest to this study is the glycosamino-
glycan hyaluronan (HA) because it is produced in large
amounts and is implicated in both inﬂammation and
ﬁbrosis.7–10
HA is a linear polymer strictly composed of repeating
disaccharide units of glucuronic acid and N-acetylglu-
cosamine and is present in most organs of the human
body.11 At the cytosolic side of the cell surface, a family of
enzymes called hyaluronan synthases creates HA poly-
mers, which are immediately extruded out of the cell.12,13
HA can exist in a range of sizes and the function of HA is
determined by its molecular weight.14 Large-molecular-
weight HA is present in most tissues, including the
May 2016 High KIAA1199 in Crohn’s Disease Fibroblasts 359intestine, and is a component of the ECM of healthy tis-
sue. Large HA is important for organ structure and ho-
meostasis, providing vital support for hydration,
lubrication, stability, and ﬂexibility. In addition, there is
evidence suggesting that large HA is anti-inﬂamma-
tory.15–17 In contrast, low-molecular-weight HA frag-
ments generally are associated with pathologic situations.
Classiﬁed as a damage-associated molecular pattern
(DAMP), fragmented HA is recognized by cell surface
immune receptors, including CD44,18,19 Toll-like receptor
(TLR) 2,17,20 and TLR4,17,21,22 on multiple cell types. A
pathophysiologically relevant outcome of these ligand-
receptor interactions is immune cell activation and pro-
motion of heightened inﬂammatory responses. Depending
on the cell type, the HA fragment–cell interaction stimu-
lates different actions, including the production of
various proinﬂammatory cytokines, such as tumor ne-
crosis factor-a (TNF-a), interleukin (IL) 1b, and IL6, and
the activation of transcription factors (nuclear factor-kB
[NF-kB], activator protein 1) that promote an immune
response.17,23,24
The process of HA fragment generation in tissues is not
well understood. The main pathway of HA degradation and
turnover in the body involves the family of hyaluronidase
(HYAL) 1 and 2 enzymes and the cell surface protein
CD44.25 In this accepted model, CD44 binds large HA onto
the cell surface, which allows HYAL2 to cut it into smaller
fragments. The fragmented HA then is internalized and
transported to the lysosome, where the acid-active enzyme
HYAL1 degrades it into oligosaccharides, which typically are
recycled.26 In a recent study investigating mechanisms of
HA degradation, the novel protein KIAA1199 was discov-
ered to play an unknown, but necessary, role in the HA
degradation process.27
KIAA1199 was ﬁrst discovered as an inner-ear protein
whose genetic mutations were linked to nonsyndromic
hearing loss.28 KIAA1199’s function in cancer metastasis
has been investigated, and recent studies have linked it to
migration, proliferation, and general survival of numerous
types of tumor cells.29–33 In addition, it was discovered that
large HA could not be degraded by cells lacking
KIAA1199,27,34 which prompted us to evaluate its potential
role in HA fragment generation, DAMP activity, and
ﬁbrogenesis.
In the present study, we used proteomic analysis of
intestinal ﬁbroblast–derived ECM and observed that CD
cells produce much higher levels of KIAA1199 protein
compared with non–inﬂammatory bowel disease (IBD) cells.
We also found higher levels in the ﬁbroblasts and the sur-
rounding medium. In addition, we showed that intestinal
ﬁbroblasts do not degrade large HA in the absence of
KIAA1199. Furthermore, we identiﬁed an IL6-dependent
autocrine mechanism underlying dysregulated KIAA1199
production by CD ﬁbroblasts. These results introduce a
novel mechanism involved in CD pathogenesis by showing
that KIAA1199 plays a key role in HA fragmentation in the
intestine and thus contributes to intestinal inﬂammation
and ﬁbrosis.Materials and Methods
All authors had access to the study data and reviewed
and approved the ﬁnal manuscript.
Cell Culture
Primary cells were isolated as previously described35
from sample tissue derived from surgically resected
colons of human Crohn’s disease or non-IBD (control; ND)
patients provided by the Department of Surgical Pathol-
ogy at the Cleveland Clinic under an Institutional Review
Board–approved protocol. After dissecting mucosal layer
strips from the colon surface, they were put through a
series of washes (dithiothreitol, D0632-10G; Sigma-
Aldrich, St. Louis, MO; for 30 minutes, Hank’s balanced
salt solution [HBSS] with penicillin-streptomycin-
fungizone, 17-745E; Lonza, Walkersville, MD; for 3
hours) before they were minced (2  2 mm) and placed
on etched marks of petri dishes and air dried for 10 mi-
nutes. Fibroblast media (Dulbecco’s modiﬁed Eagle me-
dium with high glucose, 10% fetal bovine serum (FBS
[10437-028; Gibco, Waltham, MA], 2.5% HEPES [17-
745E; Lonza, Walkersville, MD], 2% L-glutamine, and 1%
penicillin-streptomycin-fungizone) was added and the
plates were incubated at 37C in 5% CO2. When ﬁbro-
blasts grew out, the pieces were removed, and the ﬁbro-
blasts were allowed to grow to conﬂuence. Conﬂuent
stock cultures were split by routine trypsinization at a 1:2
ratio once a week. Fibroblasts were used between pas-
sages 5 and 15.Isolation and Harvest of ECM
Fibroblasts were grown for 13 days to allow for sufﬁ-
cient ECM production for detection. To isolate and harvest
ECM, cells ﬁrst were washed with HBSS, then lysed with
0.05% Triton X-100 (T8532, Sigma-Aldrich) for 10 minutes
at 37C. The lysate was aspirated and the plate was washed
with 0.025 N NH4OH for 2 minutes at room temperature.
The plate then was washed 4 times with HBSS with Ca2þ
and Mg2þ. The plate was scraped in a buffer consisting of
3% sodium dodecyl sulfate (SDS), 80 mmol/L Tris, and 10%
glycerol with freshly added protease inhibitor cocktail36
(P8340; Sigma-Aldrich).Proteomic Analysis of the Intestinal ECM
A 40-mL aliquot of each matrix sample isolated from
CD or non-IBD human intestinal ﬁbroblasts (HIF) was
used for running the SDS–polyacrylamide gel electropho-
resis (PAGE). The sample was boiled and a standard SDS-
PAGE was run on a Bio-Rad Criterion 12.5% Tris-HCl gel
with a constant voltage of 150 V. A Bio-Rad dual-color
prestained Precision Plus Protein standard (161-0374;
Bio-Rad, Hercules, CA) was run as the molecular weight
marker. The gel was ﬁxed for 30 minutes in 50% ethanol/
10% acetic acid, transferred to a plastic dish, and stained
in the dark with Sypro-ruby protein gel stain overnight.
The next morning the dye was removed, the gel was
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acid) twice for approximately 30 minutes, and equili-
brated into water (3  5 minutes). The gel was scanned
using a Typhoon Trio Imager (GE Healthcare, Piscataway,
NJ) at an excitation wavelength of 610/30 to visualize
total the protein present in the gel. The gels then were
washed in destain overnight and restained with Gel-Code
blue.
For protein digestion, the bands were cut to minimize
excess polyacrylamide and divided into a number of
smaller pieces. The gel pieces were washed with water
and dehydrated in acetonitrile. The bands then were
reduced with dithiothreitol and alkylated with iodoaceta-
mide before the in-gel digestion. All bands were treated
with trypsin, by adding 5 mL of 10 ng/mL trypsin in 50
mmol/L ammonium bicarbonate and incubating overnight
at room temperature to achieve complete digestion. The
peptides that were formed were extracted from the poly-
acrylamide in 2 aliquots of 30 mL 50% acetonitrile with
5% formic acid. These extracts were combined and evap-
orated to less than 10 mL in Speedvac (Thermo Fisher
Scientiﬁc, Waltham, MA) and then resuspended in 1%
acetic acid to make up a ﬁnal volume of approximately 30
mL for liquid chromatography–mass spectrometry (LC-MS)
analysis.
The LC-MS system was a Finnigan LTQ-Orbitrap Elite
hybrid mass spectrometer system interphased with a
Dionex Ultimate 3000 high-performance liquid chroma-
tography system (Thermo Fisher Scientiﬁc). The high-
performance liquid chromatography column was a Dionex
15 cm  75 mm internal diameter Acclaim Pepmap C18, 2
mm, 100 Å, reversed-phase, capillary chromatography col-
umn. Five microliters of the extract was injected and the
peptides were eluted from the column by an acetonitrile/
0.1% formic acid gradient at a ﬂow rate of 0.25 mL/min and
were introduced into the source of the mass spectrometer
online.
The digest was analyzed using the data-dependent
multitask capability of the instrument acquiring full scan
mass spectra to determine peptide molecular weights, and
tandem mass spectra (MS/MS) to determine amino acid
sequence in successive instrument scans.
Protein identiﬁcation was performed by analyzing all
MS/MS spectra using the Mascot program (version 2.3.02;
Matrix Science, Boston, MA), which was used to search
both the bovine and human references. These searches
were performed with a fragment ion mass tolerance of 0.8
daltons and parent ion tolerance of 10 parts per million.
Carbamidomethyl of cysteine was speciﬁed as a ﬁxed
modiﬁcation, and oxidation of methionine was speciﬁed as
a variable modiﬁcation. The relative abundance of pro-
teins in these samples was determined by comparing the
number of spectra, termed spectral counts, used to iden-
tify each protein. Normalization of spectral counts to the
total number of spectra identiﬁed for each sample was
performed before relative protein quantiﬁcation. This
approach takes into account the sample-to-sample varia-
tion that is obtained when performing replicate analyses
of a sample.Immunohistochemistry
For staining of human colon tissue sections, histochoice-
ﬁxed (H120, Amresco, Solon, OH) and parafﬁn-embedded
blocks of colon tissue from CD and non-IBD patients were
sectioned onto microscope slides and deparafﬁnized. The
section was blocked in HBSS and 2% FBS for 1 hour at room
temperature, then incubated overnight at 4C with antibody
for KIAA1199 (ab76849, 1:100; Abcam, Cambridge, MA) or
biotinylated HA binding protein (385911, 1:100; Calbio-
chem, Billerica, MA) in HBSS with 2% FBS. Coverslips were
washed 3 times with HBSS before incubation in a solution of
ﬂuorescent-tagged secondary antibody (1:1000; Life Tech-
nologies, Carlsbad, CA) in HBSS with 2% FBS for 1 hour at
room temperature. A coverslip was mounted onto the colon
section with Vectashield with 40,6-diamidino-2-phenylindole
mounting medium (H-1200; Vector Labs, Burlingame, CA).
Cultured ﬁbroblasts grown on glass coverslips for 13 days
were washed twice with HBSS and ﬁxed in ice-cold meth-
anol for 10 minutes and air-dried. Staining was performed
as described earlier. Images were obtained using a Leica DM
upright microscope (Leica, Wetzlar, Germany), with the
images taken using Image ProPlus acquisition software. The
confocal micrographs were obtained using a Leica TCS SP5
II Confocal/Multi-Photon high-speed upright microscope
with Acousto-Optical Beam Splitter and Leica confocal
software (Leica) for acquisition. Images taken for morpho-
metric immunohistochemistry were obtained at 20
magniﬁcation using a Leica Slide Scanner SCN400 (Leica)
and semiquantitative analysis was conducted using
Image ProPlus computer software (Media Cybernetics,
Rockville, MD).Immunoblot
Fibroblasts were grown for 13 days. To harvest whole-
cell lysates, cells were ﬁrst washed in ice-cold phosphate-
buffered saline twice, lysed, and scraped in a lysis buffer
that included the following: 50 mmol/L Tris-HCl (pH 7.6),
300 mmol/L NaCl, 0.5% NP-40, 1 mmol/L EDTA, and 10%
glycerol with freshly added protease inhibitor cocktail.37
The total protein of whole-cell and matrix lysates was
measured via BCA assay (23225; Pierce, Waltham, MA).
Proteins were separated via SDS-PAGE using precast Tris/
glycine-based 4%–15% gradient gels (456-1084; Bio-Rad)
run at 125 V for 1 hour. The separated proteins in the gel
were transferred onto a polyvinylidene diﬂuoride mem-
brane using a semidry transfer apparatus (170-4156; Bio-
Rad). After transfer, the membrane was blocked with 5%
milk in phosphate-buffered saline with 0.1% Tween-20
(PBST). After blocking, membranes were incubated with
primary antibody for KIAA1199 (21129-1-AP, 1:5000; Pro-
teintech, Rosemont, IL) or glyceraldehyde-3-phosphate de-
hydrogenase (ab9485, 1:10,000; Abcam) at 4C overnight.
After multiple washes, the membrane was incubated with
secondary antibody for rabbit (NA9340, 1:10,000; GE
Healthcare, Piscataway, NJ) for 1 hour at room temperature.
All membrane-washing steps were performed with PBST.
Protein bands were visualized using ECL prime chemilu-
minescent development (RPN2232; GE Healthcare) and
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Laboratory Products Sales, Inc, Rochester, NY). Differences
in chemiluminescent signal intensity were quantiﬁed using
the ImageScanner III with the ImageQuantTL v7.0 software
package (29000605; GE Healthcare, Piscataway, NJ).
Cytokines
TNF-a (#300-01A), IL1b (#200-01B), and IL6 (#200-
06) were purchased from Preprotech industries (Rocky
Hill, NJ). IL8 was from R&D Systems (#208-IL, Minneap-
olis, MN). The cytokines were used to treat cells at the
following concentrations: TNF-a at 100 U/mL, IL1b at 100
U/mL, IL6 at 20 ng/mL, and IL8 at 20 ng/mL.
For cytokine stimulation experiments, approximately
150,000 colon ﬁbroblasts were plated into each well of a
6-well plate. After allowing 3 days of growth to achieve
conﬂuence, the media was replaced with fresh media and
cytokines were added at the aforementioned concentra-
tions. The media and cytokines would be replaced every 3
days for the next 9 days. On day 13, the extracellular
matrix was collected for immunoblot analysis as previously
described.
IL6 Enzyme-Linked Immunosorbent Assay
Fibroblasts were grown for 13 days, and the media
samples were collected for IL6 analysis. The IL6 concen-
tration was measured using an enzyme-linked immunosor-
bent assay purchased from BioLegend (430504, San Diego,
CA) per the manufacturer’s instructions. The experimental
plate was incubated with capture antibody overnight at 4C.
The next day, the plate was blocked for 1 hour. Then, sample
was added and incubated for 2 hours at room temperature.
The plate then was incubated with detection antibody for 1
hour, then with avidin–horseradish-peroxidase solution for
30 minutes. Substrate solution was then added and incu-
bated for 15 minutes in the dark. A stop solution of 2 N HCl
was added after incubation with substrate solution.
Washing with PBST occurred between each step.
IL6-Receptor Blocking
CD ﬁbroblasts (w150,000) were grown for 3 days, to
reach conﬂuence, in wells of a 6-well plate. The media
then was replaced with fresh ﬁbroblast media, and IL6-
receptor (IL6R) antibody (BMS135, 1 ug/mL; eBio-
science, San Diego, CA), mouse IgG (I5381, 1 ug/mL;
Sigma-Aldrich), or media alone was added to each well.
Each day, for 10 days, fresh aliquots of IL6R antibody,
mouse IgG, or media was added to the wells at the same
concentration. At the end of the 10 days, matrix was
collected using the method described earlier.
Hyaluronan Degradation Assay
KIAA1199 was silenced using electroporation with
small interfering RNA (siRNA) previously used by Yoshida
et al27 (10620312; Invitrogen; 50-AAACAUUGAAAUAUU
CGCCAUGCUC-30). Nonsilencing control siRNA, called
scramble siRNA (12935-300; Invitrogen), was used as anegative control. Trypsinized ﬁbroblasts (w300,000) were
electroporated (VPI-1002; Lonza, Walkersville, MD) and
plated on 10-mm wells of 6-well plates with ﬁbroblast
media and incubated at 37C and 5% CO2. After 1 day of
growth, the media was replaced with modiﬁed ﬁbroblast
media, which contained only 1% FBS. The cells designated
for HA treatment were given 2 ug/mL of highly puriﬁed,
biosynthesized, 1000-kilodalton HA (HYA-1000kEF-1; Hya-
lose, Oklahoma City, OK). After 48 hours of incubation, the
media samples were collected and the whole-cell lysates
were harvested. The media then were treated with 0.25 mg/
mL Proteinase K (03115852001; Roche Applied Sciences,
Indianapolis, IN) at 60C overnight to degrade protein.38
Carbohydrate gel electrophoresis was used to deter-
mine whether the 1000-kilodalton HA was degraded.
Electrophoresis was run on a 0.5% agarose gel in Tris-
acetate-EDTA. The wells of the gel were loaded with
media samples with tracking dye run at 30 V for 30
minutes, and then at 60 V for 3.5 hours. After full sepa-
ration of carbohydrates, the gel was submerged in 0.25%
Stains All (E9379; Sigma-Aldrich) in 50% ethanol,
covered, and placed on an orbital shaker overnight at
room temperature. The gel then was destained slowly
with 10% ethanol. HA bands in the gel were scanned and
quantiﬁed using the scanning and densitometry software
previously described.38
Statistical Analyses
Statistical difference between groups was evaluated
where appropriate by the unpaired 2-tailed Student t test,
and all error bars drawn indicate the SEM. Graphing was
completed using GraphPad Prism version 4.0c (GraphPad
Software, Inc, La Jolla, CA).
Results
Proteomic Analysis of HIF-Produced ECM
We initially investigated whether the ECM produced by
HIF isolated from CD patients is quantitatively and quali-
tatively different from that of non-IBD patients, and a pro-
teomic analysis approach was used. ECM was isolated from
3 distinct CD and 2 non-IBD control colonic HIFs and sub-
jected to LC-MS analysis. Combined analysis of all the CD
and control samples identiﬁed a total of 146 unique human
proteins, with an average of 95 proteins per individual
sample. Twenty-ﬁve of the most abundantly expressed
proteins in each sample were selected for further analysis
(Supplementary Tables 1 and 2).
Of the 25 most abundant proteins in control samples, 24
also were identiﬁed among the top 25 most highly
expressed proteins in CD samples. Of these 24 shared pro-
teins, 22 were present at nearly equivalent levels in control
and CD samples (0.5- to 1.5-fold range). With respect to the
other 2 proteins, ﬁbronectin isoform 3 was overexpressed
(>1.5-fold), and ADAMSTS1 was reduced (<0.5-fold) in CD
ECM compared with ND. Interestingly, ﬁbronectin isoform 3
is among the most highly expressed proteins present in all
samples, yet its level is nearly doubled in CD compared with
control samples. Conversely, of the 25 most highly
Table 1.KIAA1199 Is Uniquely Expressed in CD Fibroblast
Matrix Only
Protein Accession
Averaged
counts
5’-nucleotidase isoform 2
preproprotein
325651886 0.7 ± 0.9
60S ribosomal protein L30 4506631 0.5 ± 0.5
Angiopoietin-related protein 2
precursor
6912236 0.7 ± 0.9
Annexin A1 4502101 0.6 ± 0.6
Laminin subunit a-5 precursor 21264602 3.8 ± 5.9
Laminin subunit g-1 precursor 145309326 2.6 ± 3.7
Protein KIAA1199 precursor 38638698 0.8 ± 0.5
Protein-glutamine
g-glutamyltransferase 2 isoform a
39777597 1.8 ± 0.1
Secreted frizzled-related protein 1
precursor
56117838 1.2 ± 1.4
Serine protease 23 precursor 6005882 0.6 ± 0.6
Secreted Protein Acidic and Rich in
Cysteine-related modular
calcium-binding protein 2 isoform
1 precursor
24308277 1.3 ± 1.2
NOTE. List of proteins found exclusively in CD matrix as
determined by mass spectrometry analysis. Two indepen-
dent experiments using 2 ND cell lines and 3 CD cell lines are
shown. Data are averaged spectral counts ± SD.
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included in the top expressed ECM proteins of control
samples (ie, basement-membrane–speciﬁc heparan sulfate
proteoglycan: <0.5-fold) (Supplementary Tables 3 and 4).
In addition, the results identiﬁed several proteins
uniquely present in the CD matrix (Table 1). Importantly,
one protein, KIAA1199, recently was found to be involved in
HA fragmentation,27 and HA is up-regulated in the tissue of
IBD patients.39 Individual sample spectral counts of
KIAA1199 of these samples are part of the data presented
above.Fibrotic CD Colon Tissue Expresses Increased
Levels of KIAA1199 Protein in the Submucosa
We previously reported the presence of high levels of HA
in the expanded muscularis mucosae region of inﬂamed CD
colon,39 and that muscularis mucosae mesenchymal cells
are a major source of HA.19 Because degradation of HA can
lead to production of fragments that have the ability to drive
mesenchymal cell proliferation and migration,40 we inves-
tigated whether KIAA1199 protein, which is involved in HA
degradation,27 is present in control or CD colon tissue. In
addition, we investigated whether KIAA1199 exists in close
proximity to its substrate, HA. Immunohistochemical anal-
ysis of ﬁbrotic CD colon tissue and non-IBD control (ND)
colon tissue was performed. Representative confocal
micrographs showed that in control colon sections,
KIAA1199 is present in the epithelium, some mononuclearleukocytes, and muscularis mucosae mesenchymal cells
(Figure 1A). In ﬁbrotic CD tissue greater levels of KIAA1199
are observed, which is especially pronounced in the
expanded submucosal region of the ﬁbrotic CD colon sec-
tions compared with controls (Figure 1B). Importantly,
KIAA1199 is abundantly expressed near HA deposits in the
inﬂamed and ﬁbrotic colon (Figure 1B), thus placing the HA
degrading protein in intimate proximity to its substrate. The
morphometrically quantiﬁed level of KIAA1199 protein in
human colons shows that CD colons have inherently higher
levels of KIAA1199 in the muscularis mucosae region of the
colon (Figure 1C).
Fibrotic CD-Derived Fibroblasts Produce
Increased KIAA1199 Protein
Based on the observation of increased expression of
KIAA1199 in and around CD mesenchymal cells in vivo
(Figure 1), we further investigated the expression and
production of KIAA1199 in cultured intestinal ﬁbroblasts.
Previous data have shown that KIAA1199 may be present
intracellularly and extracellularly.41 Fluorescence immuno-
histochemical staining of both ND and CD colon ﬁbroblasts,
grown for 13 days to allow mature matrix deposition,
consistently showed greater KIAA1199 staining in the CD
colon ﬁbroblasts compared with that of control cells
(Figure 2A). The pronounced striated appearance in the CD
cultures suggested that KIAA1199 was largely expressed
either on cell surfaces or in the ECM, and we proceeded to
assess the distribution of KIAA1199 protein in whole-cell
extracts, in the secreted compartment (culture superna-
tant), and ECM alone. Immunoblot analysis showed signiﬁ-
cantly increased KIAA1199 protein in the whole-cell lysates
(Figure 2B) and secreted fractions (Figure 2C) of CD colon
ﬁbroblasts compared with controls. Evaluation of KIAA1199
messenger RNA levels showed no signiﬁcant difference
between CD and ND colons at 13 days (data not shown).
Analyses of isolated ECM deposition both by Western blot
(Figure 2D) and mass spectrometry (Figure 2E) showed that
KIAA1199 protein level is increased in the ECM of CD colon
ﬁbroblasts compared with control cells. Importantly,
KIAA1199 is highly expressed in the ECM of cells expressing
increased collagen and ﬁbronectin (Supplementary Table 3),
proteins that are characteristic of ﬁbrosis.
IL6 Selectively Promotes Increased Deposition of
KIAA1199 in the ECM of CD Colon Fibroblasts
To understand why unstimulated CD ﬁbroblasts produce
higher levels of KIAA1199, we investigated whether cyto-
kines known to be associated with IBD pathogenesis could
modulate its production. We exposed replicate cultures of
control ﬁbroblasts to medium alone, or optimal stimulatory
amounts of TNF-a, IL1b, IL6, or IL8. A fresh dose of cytokine
was added every 3 days over the 10-day culture period.
Among the cytokines tested, only IL6 induced the increase
of KIAA1199 protein in the ECM of the stimulated control
ﬁbroblasts (Figure 3A). To determine whether IL6 could
increase KIAA1199 in the already overexpressing CD
ﬁbroblasts, we stimulated them with IL6. A signiﬁcant
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Figure 1. KIAA1199 is increased in the submucosal region of ﬁbrotic CD colons. (A) A confocal image of a human colon
tissue section from a non-IBD patient immunostained for KIAA1199 protein (red) and HA (green). (B) A confocal image of a
human colon tissue section from a ﬁbrotic CD patient immunostained for KIAA1199 protein (red) and HA (green). (C)
Morphometric analyses of KIAA1199 protein in 10 CD and 10 control patient colon sections. Data points are the percentage of
muscularis mucosae regions positive for KIAA1199 staining divided by the total muscularis mucosae areas analyzed. All data
points have been normalized to the identical area on the nonspeciﬁcally stained serial section. All images were taken with
a Leica TCS SP5 II Confocal/Multi-Photon high-speed upright microscope with Acousto-Optical Beam Splitter at 40
magniﬁcation, and acquisition was achieved with Leica confocal software. Scale bars: 100 mm. Insets are secondary antibody
only (control) stained sections (*P < .05).
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basally overexpressed level (Figure 3B).
We next asked whether CD colon ﬁbroblasts differen-
tially secreted IL6 compared with control ﬁbroblasts during
the period of increased matrix deposition. Enzyme-linked
immunosorbent assay analysis showed that supernatants
of CD ﬁbroblasts contained signiﬁcantly higher levels of IL6
compared with supernatants of control cells (Figure 3C).
To determine whether the increased secretion of IL6 by
CD ﬁbroblasts contributes to the increase of KIAA1199
protein in the ECM, we performed an IL6R-blocking exper-
iment. An anti-human IL6R-speciﬁc neutralizing antibody
was added to the CD colon ﬁbroblast cultures each day for
the 10 days after reaching conﬂuence. Immunoblot analyses
showed that blocking IL6R on CD colon ﬁbroblasts signiﬁ-
cantly decreased KIAA1199 levels in the ECM by approxi-
mately 50% (Figure 3D). Interestingly, the antibody
treatment reduced KIAA1199 to the same protein levels
typically expressed by control cells as seen in analyses inFigure 2D. These results suggest an IL6-dependent
autocrine mechanism of KIAA1199 production by CD
ﬁbroblasts.Intestinal Fibroblast-Derived KIAA1199 Promotes
HA Degradation
A crucial question in our study was whether KIAA1199
produced by intestinal ﬁbroblasts is involved in HA
degradation as reported for skin ﬁbroblasts.27 To inves-
tigate this, we used a siRNA knockdown approach and
measured degradation of puriﬁed, exogenously added,
large-molecular-weight HA. Our results show that when
KIAA1199 is silenced in ﬁbroblasts, they no longer
degrade exogenously added large-molecular-weight HA.
This is true for CD and ND colon ﬁbroblasts. Figure 4A
shows that although cells transfected with scramble
siRNA were able to degrade HA, those transfected with
speciﬁc KIAA1199-directed siRNA were completely
Figure 2. KIAA1199 is increased in ﬁbroblasts derived from CD colons compared with ﬁbroblasts from ND colons. (A)
Fluorescent images of ND and CD colon ﬁbroblasts grown for 13 days and immunostained for KIAA1199 (red) and 40,6-
diamidino-2-phenylindole (blue). Insets are secondary antibody (control) stained cells. Scale bars: 50 mm. Images were
captured on a Leica DM upright microscope at 20 magniﬁcation with Image ProPlus acquisition software. (B) Average fold-
change between densitometric measurements of immunoblots measuring KIAA1199 protein in CD and ND whole-cell lysate
normalized to glyceraldehyde-3-phosphate dehydrogenase. Six independent experiments using 10 ND cell lines and 5 CD cell
lines are shown. (C) Average fold-change between densitometric measurements from immunoblots of KIAA1199 protein in
conditioned media from CD and ND ﬁbroblasts grown for 13 days. Five independent experiments using 10 ND cell lines and 6
CD cell lines are shown. (D) Average fold-change of densitometric measurements from immunoblots comparing KIAA1199
protein in CD and ND ECM. Four independent experiments using 11 ND cell lines and 5 CD cell lines are shown. (E) Spectral
counts from mass spectrometry measuring KIAA1199 protein in the ECM of CD and ND ﬁbroblasts grown for 13 days. Two
independent experiments using 2 ND lines and 3 CD lines are shown (*P < .05).
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bohydrate sizing gel shows the dark staining band
representing the exogenous HA alone (lane 1) and the
lower-molecular-weight polydispersed band indicative of
fragmentation of the exogenous HA added to mock
silenced ﬁbroblasts (lane 2). A single band at the original1000-kilodalton size is evident in samples of HA incu-
bated with ﬁbroblasts after speciﬁcally silencing
KIAA1199 (lane 3). Importantly, the gel shows high levels
of released HA fragments in the scramble siRNA lane,
implying that these cells do not clear the cleaved frag-
ments by internalization. The inhibition of KIAA1199
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Figure 3. IL6 up-regulates KIAA1199 deposition into the ECM of colon ﬁbroblasts. (A) Average fold-change between
densitometric measurements of immunoblots measuring KIAA1199 protein in the ECM of cytokine-stimulated and unstimu-
lated ND colon ﬁbroblasts. Five independent experiments using 5 cell lines are shown. (B) Average fold-change between
densitometric measurements of immunoblots measuring KIAA1199 protein in the ECM of IL6-stimulated and unstimulated CD
colon ﬁbroblasts. Four independent experiments using 4 cell lines are shown. (C) Comparison of IL6 protein levels in the
conditioned media of CD and ND colon ﬁbroblasts after 13 days of growth. Enzyme-linked immunosorbent assay determi-
nation of supernatants from 5 ND and 4 CD cell lines is shown. (D) Average densitometric measurements of immunoblots
measuring KIAA1199 protein in the ECM of IL6R-blocking antibody–treated, mouse IgG-treated, and untreated CD colon
ﬁbroblasts. Five independent experiments using 5 cell lines are shown (*P < .05, **P < .01). Ab, antibody.
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by Western blot analysis (Figure 4B). Figure 4C shows the
quantiﬁcation of average differences in HA degradation
capability between KIAA1199 silenced cells and mock
siRNA-treated cells. Densitometric analyses of multiple
assays showed a signiﬁcant difference between the HA
degradation capability of KIAA1199 knockdown cells and
mock siRNA-transfected cells (P < .001).Discussion
Small-size HA fragments are prototypical DAMPs capable
of inducing proinﬂammatory cytokine production23 and
contributing to inﬂammation-driven ﬁbrosis.42 Our previous
work has shown that the HA content is increased and
differently organized in the intestine of active IBD patients,
as well as in the colon of mice with experimental colitis.43
This change in HA deposition is observed in the mucosal
and submucosal layers, and is especially pronounced
around muscularis mucosae cells.39 Based on these obser-
vations, we investigated whether the expanded HA matrixcould be fragmented into DAMPs that could exacerbate
inﬂammation and ﬁbrosis in IBD.
The mechanisms through which HA is cleaved from the
ECM and fragments are generated are incompletely under-
stood. Macrophages engaging in endocytosis using CD44,
the major HA receptor, are thought to play an important role
in clearing the inﬂammatory matrix and resolving tissue
inﬂammation.44 A similar mechanism previously was shown
in skin ﬁbroblasts,45 but high levels of fragment generation
seems unlikely in this process because macrophages and
ﬁbroblasts have the machinery to further degrade inter-
nalized HA to monosaccharides and disaccharides in their
lysosomes.
Our group previously showed that human platelets carry
1 of 2 somatically active hyaluronidases, HYAL2, and
platelets are capable of degrading a TNF-a–induced HA
matrix in vitro. The HA fragments generated by platelets are
released and capable of activating naive human peripheral
blood monocytes to produce IL6 and IL8 proteins.23 Further
work has shown that platelets carry HYAL2 in a granules
and must be activated to express the enzyme on their
Figure 4. Colon ﬁbroblasts cannot degrade exogenous HA
in the absence of KIAA1199. (A) Representative
carbohydrate-sizing electrophoresis gel showing hyaluronan
after incubation with media only, mock siRNA-treated colon
ﬁbroblasts, and KIAA1199-knockdown colon ﬁbroblasts. (B)
Immunoblot image detecting KIAA1199 protein in mock
siRNA and KIAA1199-knockdown colon ﬁbroblasts. Glycer-
aldehyde-3-phosphate dehydrogenase (GAPDH) band
included as loading control. (C) Average fold-change between
densitometric measurements of carbohydrate-sizing electro-
phoresis gels measuring hyaluronan after incubation with
media only, mock siRNA-treated colon ﬁbroblasts, and
KIAA1199-knockdown colon ﬁbroblasts. Nine experiments
using 9 cell lines are shown.
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deﬁcient in platelet HYAL2 protein expression.46 Platelet
cleavage of HA, however, does not seem like an efﬁcient
mechanism of HA fragment generation in solid extravascular
tissues.
In this report, we show an alternate pathway for
HA degradation, one in which mesenchymal cells of the in-
testine, being professional ECM-producing cells, could
themselves possess intrinsic mechanisms regulating ECM
turnover, speciﬁcally of HA. Recently, KIAA1199 was shown
to participate in HA degradation, and our results have
identiﬁed an overproduction of this protein speciﬁcally in
intestinal ﬁbroblasts from patients with active CD. In fact,
intestinal ﬁbroblasts functionally cleave exogenous HA, but
cells lacking KIAA1199 protein lose the ability to degrade
HA. We show that in the inﬂamed colon of CD patients there
is increased HA deposition in the submucosal and muscu-
laris mucosae areas of the intestinal wall. More importantly,
ﬁbroblasts isolated from these colons produce higher levels
of KIAA1199 than control ﬁbroblasts and this protein is
both secreted and found bound to the matrix.
We found that IL6 induces non-IBD control ﬁbroblasts
to secrete increased levels of KIAA1199 in their matrix.
Interestingly, proliferating ﬁbroblasts, both control and
CD-derived, produce comparable levels of IL6 (unpublished
data). However, differential IL6 production was observed at
conﬂuence: CD ﬁbroblasts continued to produce IL6
whereas control cell levels were greatly reduced, suggest-
ing an important change in KIAA1199 production and
regulation in the setting of chronic intestinal inﬂammation.
Antibody blockade of the IL6 receptor in CD patient ﬁbro-
blast cultures also reduces KIAA1199 protein levels,
showing that IL6, but not other proinﬂammatory cytokines,
is a selective key regulator of KIAA1199 production. This is
important because IL6 production is greatly increased in
CD tissues.47 Therefore, high levels of KIAA1199 could be
produced by autocrine IL6 as well as paracrine-supplied
IL6 produced by inﬂammatory cells during active inﬂam-
mation. This concept is supported by our ﬁnding that CD
ﬁbroblasts also deposit increased levels of KIAA1199 in
response to exogenous IL6 stimulation. Furthermore, we
have observed that IL6 containing lamina propria mono-
nuclear cell supernatant ﬂuids increase the deposition of
KIAA1199 into the ECM of non-IBD colon ﬁbroblasts (Sor-
oosh, unpublished data).
IL6 is involved in ﬁbrogenic responses, and increased
production of KIAA1199 could represent a novel proﬁbrotic
pathway. Walia et al48 have shown a regulatory relationship
between IL6 and the proﬁbrotic cytokine transforming
growth factor-b (TGFb). Other investigators49 have reported
a synergistic relationship between IL6 and TGFb in kidney
ﬁbrosis and that IL6 stimulates increased production of
collagen and various glycosaminoglycans in dermal ﬁbro-
blasts.50 Further studies have shown that ﬁbrosis stemming
from unresolved inﬂammation is strongly dependent on IL6.
This cytokine was shown to mediate T-helper cell 1 activity,
which promotes ﬁbrosis after a prolonged inﬂammatory
state, and IL6–deﬁcient mice developed less ﬁbrosis.51
May 2016 High KIAA1199 in Crohn’s Disease Fibroblasts 367Although the proﬁbrotic role of IL6 has been shown to
involve different pathways, induction of ﬁbrosis by HA
fragments generated through an IL6-stimulated production
of KIAA1199 represents an entirely novel component of
ﬁbrogenic responses, and perhaps one directly relevant to
IBD.
The ways that KIAA1199 could contribute to ﬁbrosis still
largely are unknown, but HA degradation is likely to be
involved. Interestingly, HA fragments have been shown to
stimulate production of IL6 by monocytes.23 Furthermore,
HA fragments up-regulate TGFb, expression of tissue
inhibitor of matrix metalloproteinase-1, and collagen,52 all
of which are related to ﬁbrosis. Interestingly, a recent report
showed that KIAA1199 promotes epithelial-to-
mesenchymal transition and cell survival.53 Furthermore,
Shostak et al53 provided evidence that KIAA1199 is regu-
lated by NF-kB, a well-known proinﬂammatory and proﬁ-
brotic transcription factor. Moreover, NF-kB is stimulated by
HA fragment interaction with cell surface receptors such as
CD44 and TLR4 on immune cells.54 Thus, it seems reason-
able to speculate that HA fragment-driven NF-kB signaling
increases KIAA1199, which then fosters more HA fragment
creation to drive the chronic inﬂammatory and ﬁbrotic cycle
seen in CD.
In all, our data indicate that KIAA1199 is involved in the
CD-related pathologic process stimulated by HA fragments.
Future studies will determine whether KIAA1199 produc-
tion by intestinal ﬁbroblasts mediates intestinal ﬁbrosis
through additional mechanisms.
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Supplementary Table 1.Twenty-Five Most Abundantly Expressed Proteins in ND Fibroblast Matrix With Comparison to CD
Fibroblast Matrix as Determined by Mass Spectrometry Analysis
Protein Accession
Averaged counts,
CD matrix
Averaged counts,
ND matrix Ratio CD/ND
Keratin, type II cytoskeletal 1 119395750 61.9 ± 5.4 74.3 ± 4.6 0.8
Vimentin 62414289 55.8 ± 40.8 64.8 ± 56.0 0.9
Keratin, type II cytoskeletal 2 epidermal 47132620 49.3 ± 5.9 56.9 ± 7.2 0.9
EMILIN-1 precursor 5901944 62.6 ± 5.3 56.9 ± 2.7 1.1
Tenascin precursor 153946395 63.0 ± 21.8 56.6 ± 11.1 1.1
Keratin, type I cytoskeletal 10 195972866 45.0 ± 3.7 54.5 ± 1.3 0.8
Keratin, type I cytoskeletal 9 55956899 39.6 ± 0.8 52.6 ± 7.1 0.8
TGF-b–induced protein ig-h3 precursor 4507467 38.6 ± 7.6 40.3 ± 7.5 1.0
Fibronectin isoform 3 preproprotein 16933542 54.0 ± 15.6 28.1 ± 4.4 1.9
Keratin, type II cytoskeletal 5 119395754 21.1 ± 10.7 24.9 ± 7.9 0.8
Keratin, type II cytoskeletal 6A 5031839 19.3 ± 10.6 22.2 ± 13.6 0.9
Keratin, type I cytoskeletal 14 15431310 18.6 ± 4.5 19.3 ± 8.7 1.0
A disintegrin and metalloproteinase with
thrombospondin motifs 1 preproprotein
50845384 6.7 ± 1.1 17.0 ± 6.5 0.4
Fibrillin-1 precursor 281485550 21.2 ± 7.8 15.4 ± 0.1 1.4
Serine protease HTRA1 precursor 4506141 20.2 ± 7.6 14.9 ± 3.0 1.4
Carboxypeptidase Z isoform 2 precursor 62388875 11.8 ± 3.1 13.8 ± 2.4 0.9
Desmoplakin isoform I 58530840 7.2 ± 6.9 11.4 ± 10.1 0.6
Insulin-like growth factor-binding protein 5
precursor
10834982 11.5 ± 1.1 11.2 ± 2.4 1.0
Keratin, type I cytoskeletal 16 24430192 12.4 ± 9.8 10.5 ± 8.9 1.2
40S ribosomal protein S3 15718687 5.0 ± 3.6 10.0 ± 10.5 0.5
Hornerin 57864582 8.8 ± 7.6 9.9 ± 10.7 0.9
Fibrillin-2 precursor 66346695 13.1 ± 5.2 9.7 ± 0.7 1.4
Actin, cytoplasmic 1 4501885 10.6 ± 2.7 9.4 ± 3.5 1.1
Coiled-coil domain-containing protein 80
precursor
41152074 10.6 ± 9.3 8.6 ± 5.9 1.2
Protein CYR61 precursor 31542331 8.6 ± 0.9 8.3 ± 1.3 1.0
NOTE. Two independent experiments using 2 ND cell lines and 3 CD cell lines are shown. Data are averaged spectral
counts ± SD. Bolded/shaded entries are referred to in the Results section of this article.
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Supplementary Table 2.Twenty-Five Most Abundantly Expressed Proteins in CD Fibroblast Matrix Compared With ND
Fibroblast Matrix, as Determined by Mass Spectrometry Analysis
Protein Accession
Averaged counts,
CD matrix
Averaged counts,
ND matrix Ratio CD/ND
Tenascin precursor 153946395 63.0 ± 21.8 56.6 ± 11.1 1.1
EMILIN-1 precursor 5901944 62.6 ± 5.3 56.9 ± 2.7 1.1
Keratin, type II cytoskeletal 1 119395750 61.9 ± 5.4 74.3 ± 4.6 0.8
Vimentin 62414289 55.8 ± 40.8 64.8 ± 56.0 0.9
Fibronectin isoform 3 preproprotein 16933542 54.0 ± 15.6 28.1 ± 4.4 1.9
Keratin, type II cytoskeletal 2 epidermal 47132620 49.3 ± 5.9 56.9 ± 7.2 0.9
Keratin, type I cytoskeletal 10 195972866 45.0 ± 3.7 54.5 ± 1.3 0.8
Keratin, type I cytoskeletal 9 55956899 39.6 ± 0.8 52.6 ± 7.1 0.8
TGF-b–induced protein ig-h3 precursor 4507467 38.6 ± 7.6 40.3 ± 7.5 1.0
Fibrillin-1 precursor 281485550 21.2 ± 7.8 15.4 ± 0.1 1.4
Keratin, type II cytoskeletal 5 119395754 21.1 ± 10.7 24.9 ± 7.9 0.8
Serine protease HTRA1 precursor 4506141 20.2 ± 7.6 14.9 ± 3.0 1.4
Keratin, type II cytoskeletal 6A 5031839 19.3 ± 10.6 22.2 ± 13.6 0.9
Keratin, type I cytoskeletal 14 15431310 18.6 ± 4.5 19.3 ± 8.7 1.0
Fibrillin-2 precursor 66346695 13.1 ± 5.2 9.7 ± 0.7 1.4
Keratin, type I cytoskeletal 16 24430192 12.4 ± 9.8 10.5 ± 8.9 1.2
Carboxypeptidase Z isoform 2 precursor 62388875 11.8 ± 3.1 13.8 ± 2.4 0.9
Insulin-like growth factor-binding
protein 5 precursor
10834982 11.5 ± 1.1 11.2 ± 2.4 1.0
Coiled-coil domain-containing protein
80 precursor
41152074 10.6 ± 9.3 8.6 ± 5.9 1.2
Actin, cytoplasmic 1 4501885 10.6 ± 2.7 9.4 ± 3.5 1.1
Hornerin 57864582 8.8 ± 7.6 9.9 ± 10.7 0.9
Protein CYR61 precursor 31542331 8.6 ± 0.9 8.3 ± 1.3 1.0
Basement membrane-speciﬁc
heparin sulfate proteoglycan core
protein precursor
126012571 7.6 ± 4.3 0.8 ± 0.1 9.8
Desmoplakin isoform I 58530840 7.2 ± 6.9 11.4 ± 10.1 0.6
A disintegrin and metalloproteinase
with thrombospondin motifs 1
preproprotein
50845384 6.7 ± 1.1 17.0 ± 6.5 0.4
NOTE. Two independent experiments using 2 ND cell lines and 3 CD cell lines are shown. Data are averaged spectral
counts ± SD. Bolded entries are referred to in the Results section of this article.
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Supplementary Table 3.List of Detected Proteins That Are Increased More Than 1.5-fold in the CD Fibroblast Matrix
Compared With ND Fibroblast Matrix, as Determined by Mass Spectrometry Analysis
Protein Accession
Averaged counts,
CD matrix
Averaged counts,
ND matrix Ratio CD/ND
Basement membrane-speciﬁc heparan
sulfate proteoglycan core protein
precursor
126012571 7.6 ± 4.3 0.8 ± 0.1 9.8
Myosin-Ic isoform b 124494247 0.9 ± 0.9 0.2 ± 0.3 4.5
Latent-TGF-b–binding protein 1 isoform
LTBP-1L precursor
261337165 1.1 ± 1.2 0.3 ± 0.4 4.4
Collagen a-1(XIV) chain precursor 55743096 1.4 ± 1.3 0.3 ± 0.5 4.1
Extracellular sulfatase Sulf-2 isoform a
precursor
29789100 2.2 ± 1.8 0.5 ± 0.8 4.0
Gremlin-2 precursor 71164892 1.4 ± 1.3 0.4 ± 0.6 3.3
Epidermal growth factor-like repeat and
discoidin I-like domain-containing
protein 3 precursor
31317224 2.3 ± 1.7 0.9 ± 0.2 2.6
Annexin A2 isoform 2 209862831 1.8 ± 1.6 0.8 ± 1.1 2.3
Integrin a-V isoform 2 precursor 223468595 1.7 ± 1.5 0.8 ± 1.1 2.2
Sulﬁde:quinone oxidoreductase,
mitochondrial
10864011 0.9 ± 1.0 0.4 ± 0.6 2.2
Fibronectin isoform 3 preproprotein 16933542 54.0 ± 15.6 28.1 ± 4.4 1.9
Matrilin-2 isoform b precursor 62548862 0.9 ± 0.8 0.5 ± 0.7 1.9
Integrin b-5 precursor 20127446 0.7 ± 0.6 0.4 ± 0.6 1.8
Insulin-like growth factor- binding protein 3
isoform b precursor
62243068 1.4 ± 1.0 0.8 ± 1.2 1.7
Fibulin-2 isoform a precursor 51873053 5.8 ± 3.2 3.4 ± 0.3 1.7
Epidermal growth factor-containing
ﬁbulin-like extracellular matrix protein 2
precursor
320118911 1.0 ± 1.1 0.6 ± 0.9 1.6
ADAMTS-like protein 4
isoform 1 precursor
38016904 0.9 ± 0.8 0.6 ± 0.8 1.6
Fibroleukin precursor 5730075 1.6 ± 0.5 1.0 ± 0.3 1.6
Collagen a-1(VI) chain precursor 87196339 1.0 ± 0.1 0.7 ± 0.9 1.6
Protein Wnt-5b precursor 17402919 1.9 ± 1.7 1.3 ± 0.4 1.5
NOTE. Two independent experiments using 2 ND cell lines and 3 CD cell lines are shown. Data are averaged spectral
counts ± SD.
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Supplementary Table 4.List of Detected Proteins That Are Reduced More Than 50% in the CD Fibroblast Matrix Compared
With ND Fibroblast Matrix, as Determined by Mass Spectrometry Analysis
Protein Accession
Averaged counts,
CD matrix
Averaged counts,
ND matrix Ratio CD/ND
40S ribosomal protein S10 66346695 0.6 ± 0.6 1.1 ± 1.6 0.5
40S ribosomal protein S3 4501885 5.0 ± 3.6 10.0 ± 10.5 0.5
Glyceraldehyde-3-phosphate
dehydrogenase
41152074 0.5 ± 0.8 0.9 ± 0.5 0.5
Tissue factor pathway inhibitor 2 precursor 31542331 3.1 ± 0.6 6.9 ± 0.8 0.5
A disintegrin and metalloproteinase with
thrombospondin motifs 5 preproprotein
29789100 1.8 ± 0.8 4.0 ± 1.1 0.4
Tenascin-X isoform1 precursor 71164892 1.5 ± 0.8 3.4 ± 3.4 0.4
40S ribosomal protein S5 31317224 1.0 ± 1.0 2.3 ± 2.2 0.4
Semaphorin-3B isoform 1 precursor 209862831 0.5 ± 0.5 1.2 ± 1.8 0.4
A disintegrin and metalloproteinase with
thrombospondin motifs 1 preproprotein
223468595 6.7 ± 1.1 17.0 ± 6.5 0.4
Ras-related protein Ral-A precursor 10864011 0.4 ± 0.7 1.0 ± 0.2 0.4
Calpain-1 catalytic subunit 16933542 0.2 ± 0.3 0.6 ± 0.9 0.3
40S ribosomal protein S18 62548862 1.1 ± 1.4 3.6 ± 5.1 0.3
40S ribosomal protein S16 20127446 0.7 ± 0.6 2.3 ± 2.2 0.3
Plectin isoform1 62243068 1.7 ± 3.0 7.7 ± 10.8 0.2
40S ribosomal protein S4 X isoform 51873053 0.2 ± 0.4 1.2 ± 0.6 0.2
Desmoglein-1 preproprotein 320118911 0.2 ± 0.4 1.8 ± 1.8 0.1
NOTE. Two independent experiments using 2 ND cell lines and 3 CD cell lines are shown. Data are averaged spectral
counts ± SD.
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